title: Serum ferritin predicted prognosis in patients with locally advanced pancreatic cancer.
abstract: OBJECTIVE
  The present study evaluated the value of serum ferritin (SF) level for the prognosis of patients with locally advanced pancreatic cancer (LAPC).
  
  
  METHODS
  A total of 79 patients with LAPC treated by chemoradiotherapy were reviewed retrospectively. Pretreatment and post-treatment levels of SF were obtained.
  
  
  RESULTS
  Median progression-free survival (PFS) was 11.8 months; median overall survival was 18.3 months. A total of 36 patients with elevated SF level showed significantly worse overall survival and PFS than patients with low SF level (p = 0.002 and p = 0.004, respectively). In total, 17 patients showed normal SF level after chemoradiotherapy, and their median PFS was 3.2 months longer than that of patients whose SF levels were not restored after chemoradiotherapy.
  
  
  CONCLUSIONS
  SF may serve as a valuable tool to assess prognosis and monitor chemoradiotherapy response in patients with LAPC.
authors.affiliation: Department of Medical Oncology, Shengjing Hospital of China Medical University, 36 Sanhao Road, Shenyang 110004, China.
authors.forename: Si-Liang
authors.initials: SL
authors.lastname: Wang
authors.affiliation: Department of Medical Oncology, Shengjing Hospital of China Medical University, 36 Sanhao Road, Shenyang 110004, China.
authors.forename: Shuo
authors.initials: S
authors.lastname: Cao
authors.affiliation: Department of Medical Oncology, Shengjing Hospital of China Medical University, 36 Sanhao Road, Shenyang 110004, China.
authors.forename: Rong
authors.initials: R
authors.lastname: Wu
authors.affiliation: Department of Medical Oncology, Shengjing Hospital of China Medical University, 36 Sanhao Road, Shenyang 110004, China.
authors.forename: Feng
authors.initials: F
authors.lastname: Chi
authors.affiliation: Department of Medical Oncology, Shengjing Hospital of China Medical University, 36 Sanhao Road, Shenyang 110004, China.
authors.forename: Mei-Yue
authors.initials: MY
authors.lastname: Tang
authors.affiliation: Department of Medical Oncology, Shengjing Hospital of China Medical University, 36 Sanhao Road, Shenyang 110004, China.
authors.forename: Xue-Ying
authors.initials: XY
authors.lastname: Jin
authors.affiliation: Department of Medical Oncology, Shengjing Hospital of China Medical University, 36 Sanhao Road, Shenyang 110004, China.
authors.forename: Xiao-Dong
authors.initials: XD
authors.lastname: Chen
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D005293:Ferritins / Q000097:blood*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000097:blood* / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D011878:Radiotherapy; D016896:Treatment Outcome; D047368:Tumor Burden
chemical_list: D005293:Ferritins
keywords: chemoradiotherapy; locally advanced pancreatic carcinoma; prognosis; serum ferritin